Skip to content
Biodatica
Start free

Daiichi Sankyo

Springdale, Arkansas

OncologyPhase IIListed · DSNKY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

2mo agoTrial registeredMay 15, 2026Source filing (opens the source filing in a new tab)

Momentum

75no change

Momentum 75 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Feb 26, 2024

    Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer · RECRUITING · sponsor: Daiichi Sankyo · A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    ClinicalTrials.gov · NCT06172478 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Mar 9, 2022

    Extensive-stage Small-cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Daiichi Sankyo · Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    ClinicalTrials.gov · NCT05280470 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources